|
|
|
Alteration of Metabolic Profile and Potential Biomarkers in the Plasma of Alzheimer’s Disease
|
|
Shao Yaping, Ouyang Yang, Li Tianbai, Liu Xinyao, Xu Xiaojiao, Li Song, Xu Guowang, Le Weidong
|
|
| |
| Table 1 Clinical information of the subjects in the study. |
|
| AD
(n=74) | Ctrl
(n=137) | NDC (n=31) | MCI
(n=13) | p |
|---|
| Cohort 1 | | | | | | | Number of individuals | 44 | 94 | - | - | - | | Age, mean ± SE | 72.0 ± 1.3 | 68.6 ± 0.8 | - | - | 0.0156 a | | Gender (m/f) | 20/24 | 51/43 | - | - | 0.3350 b | | Duration of disease (year) c, mean ± SE | 4.0 ± 0.5 | - | - | - | - | Disease progressiond
early/middle/late stage | 17/10/3 | - | - | - | - | | MMSE, mean ± SE e | 15.2 ± 1.0 | - | - | - | - | | MoCA, mean ± SE f | 10.9 ± 0.8 | - | - | - | - | | Cohort 2 | | | | | | | Number of individuals | 30 | 43 | 31 | 13 | - | | Age, mean ± SE | 71.6 ± 1.6 | 65.5 ± 1.2 | 62.2 ± 1.8 | 67.9 ± 2.0 | 0.0011 | | Gender (m/f) | 10/20 | 25/18 | 17/14 | 8/5 | 0.1459 | | Duration of disease (year), mean ± SE | 4.5 ± 0.5 | - | - | 3.9 ± 0.8 | 0.5852 g | Disease progression
early/middle/late stage | 14/9/4 | - | - | - | - | | MMSE, mean ± SE | 15.4 ± 1.5 | - | - | 25.1 ± 1.0 | <0.0001 | | MoCA, mean ± SE | 10.8 ± 1.5 | | | 20.0 ± 1.5 | 0.0003 |
|
|
|